SCHEMBL6740728

SCHEMBL6740728

N#CCNC(=O)C(CS(=O)(=O)Cc1ccccc1Br)NC(=O)c1ccccc1

nearest known ligand 0.69

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
CTSS P25774 12/20 0.69
CTSB P07858 12/20 0.69
CTSL P07711 9/20 0.69
CTSK P43235 6/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6740730 1.00 CTSS (0.69) CTSSCTSBCTSLCTSK
SCHEMBL6737448 0.88 CTSB (0.71) CTSSCTSBCTSLCTSK
SCHEMBL6737446 0.88 CTSB (0.71) CTSSCTSBCTSLCTSK
SCHEMBL6742015 0.88 CTSL (0.62) CTSSCTSBCTSLCTSK
SCHEMBL6742017 0.88 CTSL (0.62) CTSSCTSBCTSLCTSK
SCHEMBL6741596 0.87 CTSB (0.69) CTSSCTSBCTSLCTSK
SCHEMBL6740626 0.87 CTSL (0.69) CTSSCTSBCTSLCTSK
SCHEMBL6740630 0.87 CTSL (0.69) CTSSCTSBCTSLCTSK
SCHEMBL6741593 0.87 CTSB (0.69) CTSSCTSBCTSLCTSK
SCHEMBL6740030 0.87 CTSB (0.69) CTSSCTSBCTSLCTSK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040014796-A1 Novel compounds and compositions as cathepsin S inhititors AXYS PHARMACEUTICALS, INC. 2004-01-22 US disclosed
US-6492362-B1 Compounds and compositions as cathepsin S inhibitors AXYS PHARMACEUTICALS, INC. 2002-12-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040014796-A1 Novel compounds and compositions as cathepsin S inhititors CTSS, CTSB, CTSE CTSS 1/4885CTSB 2/4885CTSL 10/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.